On January 31, 2024, the company announced an increase in its equity buyback plan. The company increased its authorization by CNY 45 million, thereby bringing total authorization to CNY 60 million.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.12 CNY | -2.67% | -6.94% | -26.81% |
Jun. 03 | Xintian Pharmaceutical Gets Nod to Trial Chronic Non-Bacterial Prostatitis Drug; Shares Down 3% | MT |
May. 14 | Guiyang Xintian Pharmaceutical Co.,Ltd. Approves Cash Dividend for 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.81% | 275M | |
+18.49% | 80.67B | |
+13.40% | 9.17B | |
-15.14% | 4.86B | |
+45.17% | 4.55B | |
+15.70% | 4.34B | |
+16.71% | 2.38B | |
-26.13% | 2.2B | |
+15.73% | 2.1B | |
-40.52% | 1.86B |
- Stock Market
- Equities
- 002873 Stock
- News Guiyang Xintian Pharmaceutical Co.,Ltd.
- Guiyang Xintian Pharmaceutical Co.,Ltd. announces an Increase in Equity Buyback.